Zobrazeno 1 - 10
of 1 507
pro vyhledávání: '"Patient-derived xenografts"'
Autor:
Venkatachalababu Janitri, Kandasamy Nagarajan ArulJothi, Vijay Murali Ravi Mythili, Sachin Kumar Singh, Parteek Prasher, Gaurav Gupta, Kamal Dua, Rakshith Hanumanthappa, Karthikeyan Kaliappan, Krishnan Anand
Publikováno v:
MedComm, Vol 5, Iss 10, Pp n/a-n/a (2024)
Abstract Patient‐derived xenografts (PDX) involve transplanting patient cells or tissues into immunodeficient mice, offering superior disease models compared with cell line xenografts and genetically engineered mice. In contrast to traditional cell
Externí odkaz:
https://doaj.org/article/2b496cd3b52c49caa830372bd555c313
Autor:
Colin H. Quinn, Andee M. Beierle, Adele P. Williams, Raoud Marayati, Laura V. Bownes, Hooper R. Market, Michael E. Erwin, Jamie M. Aye, Jerry E. Stewart, Elizabeth Mroczek-Musulman, Karina J. Yoon, Elizabeth A. Beierle
Publikováno v:
Translational Oncology, Vol 47, Iss , Pp 102045- (2024)
Background: Pediatric gastroenteropancreatic neuroendocrine tumors are exceedingly rare, resulting in most pediatric treatment recommendations being based on data derived from adults. Trametinib is a kinase inhibitor that targets MEK1/2 and has been
Externí odkaz:
https://doaj.org/article/0515712cdd0f4633a52a9cf06e81c2dc
Autor:
Philip Prathipati, Anup S. Pathania, Nagendra K. Chaturvedi, Subash C. Gupta, Siddappa N. Byrareddy, Don W. Coulter, Kishore B. Challagundla
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 35, Iss 2, Pp 101543- (2024)
Neuroblastoma is the most devastating extracranial solid malignancy in children. Despite an intense treatment regimen, the prognosis for high-risk neuroblastoma patients remains poor, with less than 40% survival. So far, MYCN amplification status is
Externí odkaz:
https://doaj.org/article/7d9eb9261b3e4d0b860be7a5cf90ac13
Autor:
Kun Xiang, Ergang Wang, John Mantyh, Gabrielle Rupprecht, Marcos Negrete, Golshid Sanati, Carolyn Hsu, Peggy Randon, Anders Dohlman, Kai Kretzschmar, Shree Bose, Nicholas Giroux, Shengli Ding, Lihua Wang, Jorge Prado Balcazar, Qiang Huang, Pasupathi Sundaramoorthy, Rui Xi, Shannon Jones McCall, Zhaohui Wang, Chongming Jiang, Yubin Kang, Scott Kopetz, Gregory E. Crawford, Steven M. Lipkin, Xiao‐Fan Wang, Hans Clevers, David Hsu, Xiling Shen
Publikováno v:
Advanced Science, Vol 11, Iss 16, Pp n/a-n/a (2024)
Abstract Patient‐Derived Organoids (PDO) and Xenografts (PDX) are the current gold standards for patient‐derived models of cancer (PDMC). Nevertheless, how patient tumor cells evolve in these models and the impact on drug response remains unclear
Externí odkaz:
https://doaj.org/article/1bb7ddf32e6044c991fd4618eff54a98
Autor:
Fariba Nemati, Leanne de Koning, David Gentien, Franck Assayag, Emilie Henry, Khadija Ait Rais, Gaelle Pierron, Odette Mariani, Michèle Nijnikoff, Gabriel Champenois, André Nicolas, Didier Meseure, Sophie Gardrat, Nicolas Servant, Philippe Hupé, Maud Kamal, Christophe Le Tourneau, Sophie Piperno-Neumann, Manuel Rodrigues, Sergio Roman-Roman, Didier Decaudin, Pascale Mariani, Nathalie Cassoux
Publikováno v:
Current Oncology, Vol 30, Iss 10, Pp 9090-9103 (2023)
Uveal melanoma is the most common primary intraocular malignancy in adults. Up to 50% of UM patients develop metastatic disease, usually in the liver. When metastatic, the prognosis is poor, and few treatment options exist. Here, we investigated the
Externí odkaz:
https://doaj.org/article/42ff2385ab36479d9999c122c50772bb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Veronica Giusti, Giacomo Miserocchi, Giulia Sbanchi, Micaela Pannella, Claudia Maria Hattinger, Marilena Cesari, Leonardo Fantoni, Ania Naila Guerrieri, Chiara Bellotti, Alessandro De Vita, Chiara Spadazzi, Davide Maria Donati, Monica Torsello, Enrico Lucarelli, Toni Ibrahim, Laura Mercatali
Publikováno v:
Biomedicines, Vol 12, Iss 8, p 1921 (2024)
Musculoskeletal sarcomas pose major challenges to researchers and clinicians due to their rarity and heterogeneity. Xenografting human cells or tumor fragments in rodents is a mainstay for the generation of cancer models and for the preclinical trial
Externí odkaz:
https://doaj.org/article/b62b69d1957b47d4ae7db370d746fddf
Autor:
Genevieve Dall, Cassandra J. Vandenberg, Ksenija Nesic, Gayanie Ratnayake, Wenying Zhu, Joseph H. A. Vissers, Justin Bedő, Jocelyn Penington, Matthew J. Wakefield, Damien Kee, Amandine Carmagnac, Ratana Lim, Kristy Shield-Artin, Briony Milesi, Amanda Lobley, Elizabeth L. Kyran, Emily O’Grady, Joshua Tram, Warren Zhou, Devindee Nugawela, Kym Pham Stewart, Reece Caldwell, Lia Papadopoulos, Ashley P. Ng, Alexander Dobrovic, Stephen B. Fox, Orla McNally, Jeremy D. Power, Tarek Meniawy, Teng Han Tan, Ian M. Collins, Oliver Klein, Stephen Barnett, Inger Olesen, Anne Hamilton, Oliver Hofmann, Sean Grimmond, Anthony T. Papenfuss, Clare L. Scott, Holly E. Barker
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-20 (2023)
Abstract Background Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous
Externí odkaz:
https://doaj.org/article/90697e9e0fe04ca583a35a4167337ba8
RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer
Autor:
Marina Ciscar, Eva M Trinidad, Gema Perez‐Chacon, Mansour Alsaleem, Maria Jimenez, Maria J Jimenez‐Santos, Hector Perez‐Montoyo, Adrian Sanz‐Moreno, Andrea Vethencourt, Michael Toss, Anna Petit, Maria T Soler‐Monso, Victor Lopez, Jorge Gomez‐Miragaya, Clara Gomez‐Aleza, Lacey E Dobrolecki, Michael T Lewis, Alejandra Bruna, Silvana Mouron, Miguel Quintela‐Fandino, Fatima Al‐Shahrour, Antonio Martinez‐Aranda, Angels Sierra, Andrew R Green, Emad Rakha, Eva Gonzalez‐Suarez
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 4, Pp 1-12 (2023)
Abstract Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL p
Externí odkaz:
https://doaj.org/article/1a7e932a6a184ce6a384d4a58e43a0be
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 10, Pp 483-495 (2023)
Mingxun Wang,1,* Xinfei Yao,2,* Zhiyuan Bo,3,4,* Jiuyi Zheng,3 Haitao Yu,3 Xiaozai Xie,3 Zixia Lin,3 Yi Wang,5 Gang Chen,3,4 Lijun Wu3 1Department of Ultrasonography, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, P
Externí odkaz:
https://doaj.org/article/65ef06dcd198452fb48add336fe8a5e5